Missale C, Losa M, Sigala S, Balsari A, Giovanelli M, Spano P F
Division of Pharmacology and Experimental Therapeutics, School of Medicine, University of Brescia, Italy.
Mol Endocrinol. 1996 Mar;10(3):272-85. doi: 10.1210/mend.10.3.8833656.
Two different human prolactinoma phenotypes (responders and nonresponders), which are distinguished by different tumorigenic potential and different responsiveness to dopaminergic therapy, have recently been identified. Responders show low proliferation rate, low tumorigenic potential, and expression of D-2 receptors for dopamine (DA), while nonresponders are characterized by high proliferation rate, high tumorigenic potential, and lack of expression of DA D-2 receptors. In this study it has been shown that both gp140trk and gp75 components of nerve growth factor (NGF) receptor are expressed in responder prolactinoma cell lines. High levels of both NGF gene transcript and protein were also found in responders, and biologically active NGF was detectable in the media conditioned by these cells. Ablation of NGF production in responder cells by hybridization arrest of translation through NGF antisense oligonucleotides resulted in: 1) loss of secreted NGF; 2) loss of expression of gp75; 3) loss of expression of DA D-2 receptors; and 4) a remarkable increase in the cell proliferation rate. These results thus suggest that a NGF-mediated autocrine loop essential to control cell proliferation and to preserve some phenotypical characteristics of mammotroph cells is present in responder prolactinoma cell lines. Analysis of nonresponders showed that these cells express gp140trk but no detectable levels of gp75. In addition, no NGF mRNA or protein was detectable in nonresponders. Exposure of these cells to NGF resulted in the permanent expression of NGF mRNA and in the production and secretion of NGF protein, thus establishing the same NGF-mediated autocrine loop present in responders. As a result, it has been shown that nonresponder cells treated with NGF acquire and maintain most of the phenotypic characteristics of normal mammotroph cells. In conclusion, the present work reports that a NGF-mediated autocrine loop with an inhibitory role in the control of cell proliferation and tumor progression is active in the more differentiated DA-sensitive prolactinoma cell lines and is lost in the most malignant prolactinoma cells refractory to the dopaminergic therapy. Alterations in the expression of this autocrine loop thus may lead to cell transformation and tumor progression.
最近已鉴定出两种不同的人类催乳素瘤表型(反应者和无反应者),它们具有不同的致瘤潜力和对多巴胺能治疗的不同反应性。反应者表现出低增殖率、低致瘤潜力以及多巴胺(DA)D-2受体的表达,而无反应者的特征是高增殖率、高致瘤潜力以及缺乏DA D-2受体的表达。在本研究中已表明,神经生长因子(NGF)受体的gp140trk和gp75成分在反应性催乳素瘤细胞系中均有表达。在反应者中还发现了高水平的NGF基因转录本和蛋白质,并且在这些细胞条件培养基中可检测到生物活性NGF。通过NGF反义寡核苷酸使翻译杂交阻滞从而消除反应性细胞中的NGF产生,结果导致:1)分泌型NGF丧失;2)gp75表达丧失;3)DA D-2受体表达丧失;4)细胞增殖率显著增加。因此,这些结果表明,在反应性催乳素瘤细胞系中存在一个NGF介导的自分泌环,它对于控制细胞增殖和维持乳腺营养细胞的某些表型特征至关重要。对无反应者的分析表明,这些细胞表达gp140trk但未检测到gp75水平。此外,在无反应者中未检测到NGF mRNA或蛋白质。将这些细胞暴露于NGF导致NGF mRNA的永久表达以及NGF蛋白质的产生和分泌,从而建立了与反应者中相同的NGF介导的自分泌环。结果表明,用NGF处理的无反应者细胞获得并维持了正常乳腺营养细胞的大多数表型特征。总之,本研究报告称,一个在控制细胞增殖和肿瘤进展中起抑制作用的NGF介导的自分泌环在更分化的DA敏感型催乳素瘤细胞系中活跃,而在对多巴胺能治疗难治的最恶性催乳素瘤细胞中丧失。因此,这个自分泌环表达的改变可能导致细胞转化和肿瘤进展。